首页> 外文期刊>Investigational new drugs. >Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
【24h】

Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

机译:β-紫罗兰酮与索拉非尼联合使用对人肝癌SK-Hep-1细胞转移的协同作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The combination of anti-cancer drugs with nutritional factors is a potential strategy for improving the efficacy of chemotherapy, particularly for hepatocellular carcinoma because its conventional therapies are mostly ineffective. Using a highly invasive hepatoma SK-Hep-1 cell line, we investigated the possible synergistic anti-metastatic efficacy of a combination of sorafenib (SF), a multi-kinase inhibitor, and β-ionone (BI), a precursor of carotenoids. We found that SF (1 μM) in combination with BI (1 μM) synergistically inhibited cell invasion and additively inhibited cell migration, especially at 48 h of incubation. Mechanistically, the combination of SF and BI was found to decrease the protein expression of focal adhesion kinase (FAK) and Rho, and to enhance the protein expression of tissue inhibitor matrix metalloproteinase (TIMP)-1 and TIMP-2. In addition, the combination of SF and BI inhibited the activity of matrix metalloproteinase (MMP)-2 and MMP-9 and decreased the phosphorylation of FAK and of Rac1 proteins. Importantly, SF enhanced the suppressing effect of BI (1-50 μM) on the viability of SK-Hep-1 cells, but not on murine hepatic BNL CL.2 cells, indicating the selective cytotoxicity of this combination on tumor cells. The combination of SF and BI could be a potential therapeutic strategy against human hepatoma cells.
机译:将抗癌药物与营养因子结合使用是提高化疗疗效的潜在策略,特别是对于肝细胞癌,因为其常规疗法大多无效。使用高侵袭性肝癌SK-Hep-1细胞系,我们研究了多激酶抑制剂索拉非尼(SF)和类胡萝卜素前体β-紫罗兰酮(BI)组合可能产生的协同抗转移功效。我们发现SF(1μM)与BI(1μM)组合可协同抑制细胞侵袭并累加抑制细胞迁移,尤其是在孵育48小时时。从机制上讲,发现SF和BI的组合可降低粘着斑激酶(FAK)和Rho的蛋白表达,并增强组织抑制剂基质金属蛋白酶(TIMP)-1和TIMP-2的蛋白表达。此外,SF和BI的组合抑制基质金属蛋白酶(MMP)-2和MMP-9的活性,并降低FAK和Rac1蛋白的磷酸化。重要的是,SF增强了BI(1-50μM)对SK-Hep-1细胞活力的抑制作用,但对鼠肝BNL CL.2细胞没有抑制作用,表明该组合对肿瘤细胞的选择性细胞毒性。 SF和BI的组合可能是针对人肝癌细胞的潜在治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号